This consensus statement from the European Neuroendocrine Society is based on extensive bibliographic searches and systematic review. Surgery is the mainstay of therapy for most tumors, and includes resection of metastases when this can be accomplished in a curative manner. Somatostatin analogues are considered first line therapy for unresectable c
ALERT!
This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
Lung Cancer - Multimodality Therapy
February 2, 2015
The authors queried the National Cancer Data Base to assess outcomes of patients with R1 resection margins related to the presence and type of postoperative adjuvant therapy. 3.1% of over 54,000 resections had R1 margins, which negatively affected long-term survival. Combined chemotherapy and radiation therapy improved outcomes; administration of c
November 11, 2014
This study explored financial conflicts of interest (FCOI) among authors of published guidelines and consensus statements and their relationship to endorsement of specific drugs. 93% of recent articles reported FCOI status. Of articles publishing funding sources, 65% reported partial or full industry funding. Endorsement of chemotherapeutic agents
October 15, 2014
It seems that patients with lung or colorectal cancer have poor enrollment in clinical trials, according to the recent multiregional survey carried out by the authors in a cohort of 8778 patients three to six months after diagnosis. Only 14% of patients have discussed their participation in clinical trials.
August 5, 2014
Optimal management of superior sulcus tumors remains challenging. This SWOG protocol was a feasibility study of the utility of consolidation therapy with docetaxel in addition to cisplatin-etoposide, 45Gy, and possible resection. Of 46 registered pts, 86% completed induction therapy, 66% underwent resection, and 45% completed consolidation therapy
Pages
- « first
- ‹ previous
- 1
- 2
- 3
- 4